Tag Archives: Palomar Medical Technologies

Law Office of Brodsky & Smith, LLC Announces Investigation of Palomar Medical Technologies, Inc.

By Business Wirevia The Motley Fool

Filed under:

Law Office of Brodsky & Smith, LLC Announces Investigation of Palomar Medical Technologies, Inc.

BALA CYNWYD, Pa.–(BUSINESS WIRE)– Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Palomar Medical Technologies, Inc. (“Palomar Medical” or the “Company”) (NAS: PMTI) relating to the proposed acquisition by Cynosure, Inc.

Under the terms of the transaction, Palomar Medical shareholders will receive only $6.8525 in cash and $6.825 in Cynosure common stock (subject to adjustment), for each share of Palomar Medical stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Palomar Medical for not acting in the Company’s shareholders’ best interests in connection with the sale process. The transaction may undervalue the Company and will result in loss for many long term Palomar Medical shareholders. For example Palomar Medical stock traded at $14.18 as recently as May 31, 2011 and $16.01 on April 29, 2011. In addition, the price being offered is below an analyst price target of $14.50 per share for Palomar Medical stock.

If you own shares of Palomar Medical stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/556-pmti-palomar-mecical-technologies-inc.html, by calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
investorrelations@brodsky-smith.com
http://brodsky-smith.com/556-pmti-palomar-mecical-technologies-inc.html

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:

The article Law Office of Brodsky & Smith, LLC Announces Investigation of Palomar Medical Technologies, Inc. originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

From: http://www.dailyfinance.com/2013/04/11/law-office-of-brodsky-smith-llc-announces-investig/

Why Palomar Medical Technologies May Be About to Take Off

By Seth Jayson, The Motley Fool

Filed under:

Here at The Motley Fool, I’ve long cautioned investors to keep a close eye on inventory levels. It’s a part of my standard diligence when searching for the market’s best stocks. I think a quarterly checkup can help you spot potential problems. For many companies, products that sit on the shelves too long can become big trouble. Stale inventory may be sold for lower prices, hurting profitability. In extreme cases, it may be written off completely and sent to the shredder.

Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven’t materialized. Is the current inventory situation at Palomar Medical Technologies (NAS: PMTI) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Palomar Medical Technologies doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue decreased 22.1%, and inventory increased 1.9%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue grew 4.4%, and inventory increased 1.9%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 26.9%, and inventory dropped 10.9%.

Advanced inventory

I don’t stop my checkup there, because the type of inventory can matter even more than the overall quantity. There’s even one type of inventory bulge we sometimes like to see. You can check for it by examining the quarterly filings to evaluate the different kinds of inventory: raw materials, work-in-progress inventory, and finished goods. (Some companies report the first two types as a single category.)

A company ramping up for increased demand may increase raw materials and work-in-progress inventory at a faster rate when it expects robust future growth. As such, we might consider oversized growth in those categories to offer a clue to a brighter future, and a clue that most other investors will miss. We call it “positive inventory divergence.”

On the other hand, if we see a big increase in finished goods, that often means product isn’t moving as well as expected, and it’s time to hunker down with the filings and conference calls to find out why.

What’s going on with the inventory at Palomar Medical Technologies? I chart the details below for both quarterly and 12-month periods.

Source: S&P Capital IQ. Data is current as of latest fully reported quarter. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.

<div …read more
Source: FULL ARTICLE at DailyFinance

Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its

By Business Wirevia The Motley Fool

Filed under:

Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its Sale to Cynosure, Inc. – PMTI

NEW YORK–(BUSINESS WIRE)– The Rosen Law Firm, P.A. is investigating the Board of Directors of Palomar Medical Technologies, Inc. (“Palomar” or the “Company”) (NASDAQ GS: PMTI) for possible breaches of fiduciary duty and other violations of state law in connection with its sale of the Company to Cynosure, Inc. (NASDAQ GS: CYNO).

If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the transaction, shareholders will receive $13.65 for each share of Palomar stock they own – $6.825 per share in cash and $6.825 per share in Cynosure common stock. The investigation relates to whether the price of $13.65 per share in cash and Cynosure stock is fair to public shareholders and whether PMTI‘s Board breached its fiduciary duties in connection with the transaction.

If you own Palomar common stock and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

The Rosen Law Firm P.A.
Phillip Kim, Esq.
Laurence Rosen, Esq.
275 Madison Avenue 34th Floor
New York, New York 10016
Tel: 212-686-1060
Weekends Tel: 917-562-8616
Toll Free: 1-866-767-3653
Fax: 212-202-3827
pkim@rosenlegal.com
lrosen@rosenlegal.com
www.rosenlegal.com

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:

The article Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its Sale to Cynosure, Inc. – PMTI originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure …read more
Source: FULL ARTICLE at DailyFinance

Cynosure to Acquire Palomar Medical Technologies

By Eric Volkman, The Motley Fool

Filed under:

Cynosure has inked a definitive agreement to acquire Palomar Medical Technologies . The purchase will be a mix of stock and cash at a total value of roughly $294 million. Palomar shareholders will receive $13.65 per share in the buyout — half in stock and half in cash.

The company’s stock closed at $13.17 after the deal was announced.

The move is seen as a highly synergistic one for Cynosure, as the two firms manufacture broadly similar products and both are based in Massachusetts. Combined, the companies boast a total installed base of more than 20,000 aesthetic laser systems throughout the world and a distribution network that covers more than 100 countries. Their combined 2012 revenue was around $234 million.

The article Cynosure to Acquire Palomar Medical Technologies originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';

var s = document.getElementsByTagName('script')[0];
s.parentNode.insertBefore(ga, s);
})();

Read | Permalink | Email this | Linking Blogs | Comments

…read more
Source: FULL ARTICLE at DailyFinance

Law Firm Brower Piven Announces Investigation of Palomar Medical Technologies, Inc. Proposed Buyout

By Business Wirevia The Motley Fool

Filed under:

Law Firm Brower Piven Announces Investigation of Palomar Medical Technologies, Inc. Proposed Buyout

STEVENSON, Md.–(BUSINESS WIRE)– The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Palomar Medical Technologies, Inc. (“Palomar” or the “Company”) (NAS: PMTI) and other violations of state law by the board of directors of Palomar relating to the proposed buyout of the Company by Cynosure, Inc. (“Cynosure”). The firm’s investigation seeks to determine, among other things, whether Palomar’s board of directors breached their fiduciary duties by failing to maximize shareholder value.

As stated in the press release announcing the proposed buyout, Palomar shareholders will receive $13.65 for each share of Palomar they own, which includes $6.825 per share in cash and $6.825 per share in Cynosure common stock. However, according to Yahoo! Finance, the high analyst price target is $14.50 per Palomar share.

If you currently own common stock of Palomar and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.

Brower Piven, A Professional Corporation
Stevenson, Maryland
Charles J. Piven, 410-415-6616
hoffman@browerpiven.com

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:

The article Law Firm Brower Piven Announces Investigation of Palomar Medical Technologies, Inc. Proposed Buyout originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
…read more
Source: FULL ARTICLE at DailyFinance

Palomar Medical Shareholder Alert: Briscoe Law Firm and Powers Taylor, LLP Investigate Sale to Cynos

By Business Wirevia The Motley Fool

Filed under:

Palomar Medical Shareholder Alert: Briscoe Law Firm and Powers Taylor, LLP Investigate Sale to Cynosure

DALLAS–(BUSINESS WIRE)– Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Palomar Medical Technologies, Inc. (“Palomar”) (NasdaqGS: PMTI) to Cynosure, Inc. for shareholders. Under the terms of the proposed transaction valued at approximately $294 million, Palomar shareholders will only receive $13.65 in consideration: $6.825 in cash and $6.825 in Cynosure common stock (subject to adjustment), for each share of Palomar stock owned, well below at least one analyst’s estimated value of $14.50 per share.

If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com, or Zach Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at zach@powerstaylor.com. There is no cost or fee to you.

The Palomar sale investigation centers on whether Palomar’s shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues Palomar’s stock, and whether Palomar’s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. Notably, at least one analyst with Yahoo! Finance has estimated that the true inherent value of Palomar shares could be as high as $14.50 per share. Shareholder rights attorney Patrick Powers stated that “due to proposed sale price, analysts’ estimates, the size of the deal and other factors, we believe this transaction may undervalue Palomar’s stock. Our proposed lawsuit will seek to ensure that shareholders are receiving the highest share price for their shares.”

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

The Briscoe Law Firm, PLLC
Willie Briscoe, 214-239-4568
WBriscoe@TheBriscoeLawFirm.com
or
Powers Taylor, LLP
Zach Groover, 877-728-9607
zach@powerstaylor.com

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:

…read more
Source: FULL ARTICLE at DailyFinance

Rigrodsky &amp; Long, P.A. Announces Investigation Of Palomar Medical Technologies, Inc. Buyout

By Business Wirevia The Motley Fool

Filed under:

Rigrodsky & Long, P.A. Announces Investigation Of Palomar Medical Technologies, Inc. Buyout

WILMINGTON, Del.–(BUSINESS WIRE)– Rigrodsky & Long, P.A.:

  • Do you own shares of Palomar Medical Technologies, Inc. (NASDAQ GS: PMTI )?
  • Did you purchase any of your shares prior to March 18, 2013?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Palomar Medical Technologies, Inc. (“Palomar” or the “Company”) (NASDAQ GS: PMTI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Cynosure, Inc. (“Cynosure”) (NASDAQ GS: CYNO) in a transaction valued at approximately $294 million.

Click here to learn more: http://www.rigrodskylong.com/investigations/palomar-medical-technologies-inc-pmti.

Under the terms of the proposal, public shareholders of Palomar will receive $13.65 per share of Palomar common stock: $6.825 per share in cash and $6.825 per share in Cynosure common stock.

The investigation concerns whether Palomar’s board of directors failed to adequately shop the Company and obtain the best possible value for Palomar’s shareholders before entering into an agreement with Cynosure. According to Yahoo! Finance, at least one analyst has set a price target for Palomar stock at $14.50 per share.

If you own the common stock of Palomar and purchased your shares before March 18, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth Rigrodsky or Brian Long at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, Delaware 19803, by telephone at (302) 295-5310, or Peter Allocco at Rigrodsky & Long, P.A., …read more
Source: FULL ARTICLE at DailyFinance